EG24716A - Combination of organic compounds - Google Patents

Combination of organic compounds

Info

Publication number
EG24716A
EG24716A EG2003050449A EG2003050449A EG24716A EG 24716 A EG24716 A EG 24716A EG 2003050449 A EG2003050449 A EG 2003050449A EG 2003050449 A EG2003050449 A EG 2003050449A EG 24716 A EG24716 A EG 24716A
Authority
EG
Egypt
Prior art keywords
combination
organic compounds
compounds
organic
Prior art date
Application number
EG2003050449A
Other languages
English (en)
Inventor
Suraj S Shetty
Randy L Webb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of EG24716A publication Critical patent/EG24716A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
EG2003050449A 2002-05-17 2003-05-14 Combination of organic compounds EG24716A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38154702P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
EG24716A true EG24716A (en) 2010-06-07

Family

ID=29550142

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2003050449A EG24716A (en) 2002-05-17 2003-05-14 Combination of organic compounds

Country Status (30)

Country Link
US (3) US20050222137A1 (xx)
EP (1) EP1507529B8 (xx)
JP (2) JP5132872B2 (xx)
KR (2) KR20050000546A (xx)
CN (2) CN101890166A (xx)
AR (1) AR040014A1 (xx)
AT (1) ATE429223T1 (xx)
AU (1) AU2003240261B2 (xx)
BR (1) BR0310092A (xx)
CA (1) CA2486144C (xx)
CY (1) CY1109240T1 (xx)
DE (1) DE60327316D1 (xx)
DK (1) DK1507529T3 (xx)
EC (1) ECSP045429A (xx)
EG (1) EG24716A (xx)
ES (1) ES2325207T3 (xx)
HK (1) HK1074773A1 (xx)
IL (1) IL164925A (xx)
MX (1) MXPA04011385A (xx)
MY (1) MY138838A (xx)
NO (1) NO333011B1 (xx)
NZ (1) NZ536557A (xx)
PE (1) PE20040439A1 (xx)
PL (1) PL372369A1 (xx)
PT (1) PT1507529E (xx)
RU (1) RU2324482C2 (xx)
SI (1) SI1507529T1 (xx)
TW (1) TWI358291B (xx)
WO (1) WO2003097045A1 (xx)
ZA (1) ZA200408737B (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR20120058618A (ko) * 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
ATE437641T1 (de) 2003-05-15 2009-08-15 Roskamp Res Llc Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
EP1631556A1 (en) * 2003-05-16 2006-03-08 Novartis AG Pharmaceutical composition comprising valsartan
WO2005014043A1 (en) * 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
WO2005082329A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
EP1813274B1 (en) * 2004-10-06 2009-12-16 Eisai R&D Management Co., Ltd. Medicinal composition, process for producing the same, and method of stabilizing dihydropyridine compound in medicinal composition
SI1814527T1 (sl) * 2004-11-05 2014-03-31 Boehringer Ingelheim International Gmbh Dvoslojna tableta, ki obsega telmisartan in amlodipin
CN1830454A (zh) * 2005-03-10 2006-09-13 刘智仁 盐酸在制备治疗高血压药物中的应用
EP1872783B1 (en) * 2005-04-21 2011-12-28 Santen Pharmaceutical Co., Ltd. Therapeutic agent for corneal/conjunctival disorder
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
JP5063370B2 (ja) * 2005-06-27 2012-10-31 第一三共株式会社 湿式造粒製薬の調製方法
US20080279942A1 (en) * 2005-06-27 2008-11-13 Takeshi Hamaura Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker
DE102005031577A1 (de) 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
JP2009532498A (ja) * 2006-04-06 2009-09-10 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ
PE20080991A1 (es) * 2006-06-27 2008-09-05 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
GB2471970A (en) * 2006-09-15 2011-01-19 Daiichi Sankyo Co Ltd Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide
CN101199848B (zh) * 2006-11-11 2012-05-23 深圳奥萨医药有限公司 钙通道阻滞剂/利尿剂/叶酸联用的药物组合物及其用途
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
RU2490014C2 (ru) 2007-10-05 2013-08-20 Альцгеймер'С Инститьют Оф Америка, Инк. Способ уменьшения отложения амилоида, амилоидной нейротоксичности и микроглиоза с помощью (-)-энантиомера нилвадипина
EP2240163A1 (en) * 2007-12-31 2010-10-20 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
WO2010006103A1 (en) * 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Method for enhancing cognition or inhibiting cognitive decline
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
WO2010085014A1 (en) 2009-01-23 2010-07-29 Hanmi Pharm. Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
TR201102067A1 (tr) 2011-03-03 2012-09-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Valsartan ve amlodipin kombinasyonları.
GB201116993D0 (en) 2011-10-03 2011-11-16 Ems Sa Pharmaceutical compositions of antihypertensives
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
SG11201406363VA (en) 2012-05-07 2014-11-27 Bayer Pharma AG Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
WO2013191668A1 (en) 2012-06-22 2013-12-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions preventing hypertension comprising soluplus
MX358211B (es) * 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
US10918612B2 (en) * 2013-01-22 2021-02-16 Markus Zwickl Combinations with 2-aminoethanesulfonic acid
ES2847904T3 (es) * 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicamento para la prevención o el tratamiento de la hipertensión
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
FR3014694B1 (fr) 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
CN104324377B (zh) * 2014-06-19 2017-08-04 西安力邦肇新生物科技有限公司 一种复方降压制剂及其应用
KR101914930B1 (ko) * 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
CN105106962A (zh) * 2015-08-29 2015-12-02 西安力邦肇新生物科技有限公司 一种复方降压制剂及其应用
WO2017164208A1 (ja) * 2016-03-24 2017-09-28 第一三共株式会社 腎疾患の治療のための医薬
US10319209B2 (en) 2016-06-03 2019-06-11 John Carlton-Foss Method and system for motion analysis and fall prevention
KR20180053044A (ko) * 2016-11-11 2018-05-21 주식회사유한양행 클로르탈리돈 또는 이의 염 및 암로디핀 또는 이의 염을 포함하는 단일 매트릭스 정제 형태의 약학 조성물 및 이의 제조방법
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
JP2020506180A (ja) 2017-01-25 2020-02-27 ザ ジョージ インスティテュート フォー グローバル ヘルス 高血圧症の処置のための組成物
UA126122C2 (uk) * 2017-02-27 2022-08-17 Ідорсія Фармасьютікалз Лтд Комбінації похідної 4-піримідинсульфаміду з активними інгредієнтами для лікування захворювань, пов'язаних з ендотеліном
US20200030296A1 (en) 2018-07-26 2020-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
CN111789843A (zh) * 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης
KR20240014345A (ko) 2022-07-25 2024-02-01 안국약품 주식회사 암로디핀, 발사르탄 및 인다파미드를 포함하는 약학 제제 및 이의 제조 방법

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
CA2016710A1 (en) 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
US5449682A (en) 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
ES2084801T3 (es) 1990-02-19 1996-05-16 Ciba Geigy Ag Acil compuestos.
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
CA2098176C (en) 1990-12-14 2006-12-12 Joseph Weinstock Angiotensin ii receptor blocking compositions
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
US5492904A (en) 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
US5260325A (en) 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
US5202322A (en) 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
US5206348A (en) 1992-07-23 1993-04-27 Morton International, Inc. Hexahydroxybenzophenone sulfonate esters of diazonaphthoquinone sensitizers and positive photoresists employing same
US5264447A (en) 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
US5266583A (en) 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
JPH09508641A (ja) 1994-02-08 1997-09-02 チバーガイギー アクチエンゲゼルシャフト アンギオテンシン▲ｉｉ▼拮抗薬による正常眼圧緑内障の治療
WO1995024901A1 (en) 1994-03-17 1995-09-21 Ciba-Geigy Ag Treatment of diabetic nephropathy with valsartan
GB9406573D0 (en) 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
RO118870B1 (ro) 1996-03-29 2003-12-30 Smithkline Beecham Corporation Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5949290A (en) * 1997-01-14 1999-09-07 Bertram; Earnest L. Voltage controlled oscillator tuning apparatus and method
AU743028B2 (en) 1997-04-11 2002-01-17 President And Fellows Of Harvard College Molecules presenting a multitude of active moieties
US5991348A (en) * 1997-08-12 1999-11-23 3Com Corporation Method and apparatus for regenerating symbol timing from a probing signal in a system having non-linear network and codec distortion
DE19820151A1 (de) * 1998-05-06 1999-11-11 Hexal Ag Transdermales therapeutisches System zur Anwendung von Candesartan
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
EP2322174B1 (en) * 1998-07-10 2015-09-23 Novartis Pharma AG Combined use of valsartan and calcium channel blockers for therapeutic purposes
KR100646716B1 (ko) 1998-12-23 2006-11-17 노파르티스 아게 Ａｔ-1 또는 ａｔ-2 수용체의 증가와 관련된 질환의치료에 있어서 ａｔ-1 수용체 길항제 또는 ａｔ-2 수용체조절제의 용도
CZ20012682A3 (cs) 1999-01-26 2001-10-17 Novartis Ag Pouľití antagonistů receptoru angiotensinu II pro léčení akutního infarktu myokardu
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
CN1301545A (zh) 1999-12-27 2001-07-04 王德山 一种复方降血压药
DE10004651A1 (de) 2000-02-03 2001-08-16 Jutta Dierkes Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
AU2001289672B2 (en) 2000-07-19 2005-12-08 Novartis Ag Valsartan salts
CA2430924A1 (en) 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas

Also Published As

Publication number Publication date
AU2003240261B2 (en) 2007-06-28
CY1109240T1 (el) 2014-07-02
DK1507529T3 (da) 2009-08-03
PL372369A1 (en) 2005-07-25
KR20050000546A (ko) 2005-01-05
US20120115854A1 (en) 2012-05-10
HK1074773A1 (en) 2005-11-25
CA2486144A1 (en) 2003-11-27
MY138838A (en) 2009-07-31
CN1652777A (zh) 2005-08-10
BR0310092A (pt) 2005-02-15
IL164925A (en) 2014-04-30
ATE429223T1 (de) 2009-05-15
JP5132872B2 (ja) 2013-01-30
ECSP045429A (es) 2005-01-03
MXPA04011385A (es) 2005-02-14
PE20040439A1 (es) 2004-08-20
US20090099241A1 (en) 2009-04-16
AR040014A1 (es) 2005-03-09
KR20110107877A (ko) 2011-10-04
SI1507529T1 (sl) 2009-10-31
IL164925A0 (en) 2005-12-18
JP2005533023A (ja) 2005-11-04
NO20045429L (no) 2004-12-13
WO2003097045A1 (en) 2003-11-27
TW200406204A (en) 2004-05-01
NO333011B1 (no) 2013-02-18
ES2325207T3 (es) 2009-08-28
JP2010209123A (ja) 2010-09-24
RU2324482C2 (ru) 2008-05-20
TWI358291B (en) 2012-02-21
NZ536557A (en) 2006-10-27
EP1507529A1 (en) 2005-02-23
KR101454070B1 (ko) 2014-10-23
EP1507529B1 (en) 2009-04-22
US8101599B2 (en) 2012-01-24
CA2486144C (en) 2012-02-07
RU2004137105A (ru) 2005-09-10
DE60327316D1 (de) 2009-06-04
CN101890166A (zh) 2010-11-24
PT1507529E (pt) 2009-07-24
AU2003240261A1 (en) 2003-12-02
ZA200408737B (en) 2006-02-22
EP1507529B8 (en) 2010-02-24
US20050222137A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
EG24716A (en) Combination of organic compounds
GB0212412D0 (en) Combination of organic compounds
GB0203276D0 (en) Organic compounds
GB0202873D0 (en) Organic compounds
GB0209265D0 (en) Organic compounds
GB0205281D0 (en) Organic compounds
GB0200429D0 (en) Organic compounds
EG23462A (en) Organic compounds
GB0209481D0 (en) Organic compounds
GB0203061D0 (en) Organic compounds
GB0204756D0 (en) Organic compounds
GB0202874D0 (en) Organic compounds
GB0209257D0 (en) Organic compounds
GB0207496D0 (en) Organic compounds
GB0209883D0 (en) Organic compounds
GB0207729D0 (en) Organic compounds
GB0207728D0 (en) Organic compounds
GB0207726D0 (en) Organic compounds
GB0207506D0 (en) Organic compounds
GB0207504D0 (en) Organic compounds
GB0207503D0 (en) Organic compounds
GB0207500D0 (en) Organic compounds
GB0207499D0 (en) Organic compounds
GB0209882D0 (en) Organic compounds
GB0206694D0 (en) Organic compounds